Real-world clinical outcome and safety of adjuvant human Interferon-alpha1b in resected stageⅢB orⅢC melanoma:results of a retrospective study  

作　　者：Meiyan Gao Yuehua Li Wenjing Tang Yu Liu Weinan Guo Tao Zhao Jianhong Zhao Jin’e Zhang Guannan Zhu Chunying Li Tianwen Gao Qiong Shi 

机构地区：[1]Department of Dermatology,Xijing Hospital,Fourth Military Medical University,Xi’an 710032,Shaanxi,China

出　　处：《Holistic Integrative Oncology》2024年第1期501-509,共9页整合肿瘤学(英文)

基　　金：funded by National Natural Science Foundation of China(No.82273716);National Key Research and Development Program of China(2021YFA1101003);Young Eagle Project of Fourth Military Medical University(No.2020cyjhsq);National Natural Science Foundation of China(No.82172607 and 82273182).

摘　　要：Background Human interferon-α1b(hIFN-α1b)is the first genetically engineered drug approved by the National Medical Product Administration for cancer therapy in China.hIFN-α1b is a relatively safe therapy and can improve survival in advanced melanoma and its long-term efficacy against resection of stage Ⅲ melanoma is unknown.Objective The objective of this study is to assess the safety and efficacy of hIFN-α1b in patients with resected stage Ⅲ melanoma.Methods The clinical data were collected from patients who underwent resection of stage ⅢB or ⅢC melanoma and received subcutaneous injection of hIFN-α1b every other day.The efficacy of hIFN-α1b was determined by rate of recurrence-free survival(RFS),distant metastasis-free survival(DMFS)and overall survival(OS).Safety data were acquired by review of adverse events at follow-ups.Results The study included a total of 61 patients.The median follow-up duration was 45 months.The RFS at 12,24,and 36 months were observed to be 75.4%,47.4%,and 37.2%respectively,while the DMFS rates were found to be 83.6%,65.5%,and 62.2%.Furthermore,the OS rates at these time points were recorded as being 100%,81.9%,and 71.5%.The overall tolerability of hIFN-α1b was satisfactory,with only 8.2%of the patients experiencing grade 3/4 toxicity and no treatment-related deaths observed.Conclusion Our findings suggest that adjuvant hIFN-α1b treatment is relatively safe and may potentially enhance the rate of RFS,DMFS and OS in patients who have undergone resection for stage ⅢB or ⅢC melanoma.

关 键 词：MELANOMA Human Interferon-α1b Adjuvant therapy Adverse event EFFICACY Retrospective study 

分 类 号：R73[医药卫生—肿瘤]